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Abstract
 
Dendritic cells (DCs)
 
*
 
 fulfill an important regulatory function at the interface of the innate and
adaptive immune system. The thymus and activation-regulated chemokine (TARC/CCL17) is
produced by DCs and facilitates the attraction of activated T cells. Using a fluorescence-based
in vivo reporter system, we show that CCL17 expression in mice is found in activated Langer-
hans cells and mature DCs located in various lymphoid and nonlymphoid organs, and is up-
regulated after stimulation with Toll-like receptor ligands. DCs expressing CCL17 belong to
the CD11b
 
 
 
CD8
 
 
 
Dec205
 
 
 
 DC subset, including the myeloid-related DCs located in the sub-
epithelial dome of Peyer’s patches. CCL17-deficient mice mount diminished T cell–dependent
contact hypersensitivity responses and display a deficiency in rejection of allogeneic organ
transplants. In contrast to lymphoid organs located at external barriers of the skin and mucosa,
CCL17 is not expressed in the spleen, even after systemic microbial challenge or after in vitro
stimulation. These findings indicate that CCL17 production is a hallmark of local DC stimula-
tion in peripheral organs but is absent from the spleen as a filter of blood-borne antigens.
Key words: CCL17/TARC • dendritic cells • transplant rejection • contact hypersensitivity • 
Toll-like receptors
 
Introduction
 
Efficient activation of T lymphocytes requires the recogni-
tion of peptide/MHC complexes and costimulatory mole-
cules on the surface of professional APCs in the environ-
ment of organized secondary lymphoid tissues. Dendritic
cells (DCs)
 
*
 
 represent professional APCs, able to transport
antigen from sites of infection to the local draining LNs and
to initiate primary immune responses (1, 2). In addition to
membrane-bound receptor/ligand interactions, the secre-
tion of chemokines and immunostimulatory cytokines by
DCs is required for optimal attraction and differentiation of
antigen-specific T cells. Several subsets of DCs have been
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Abbreviations used in this paper:
 
 BM, bone marrow; CHS, contact hypersen-
sitivity; cLN, cutaneous lymph node; CRP, C-reactive protein; DC,
dendritic cell; DNFB, dinitrofluorobenzene; EGFP, enhanced green fluo-
rescent protein; LC, Langerhans cell; LP, lamina propria; MACS, mag-
netic-activated cell sorting; mLN, mesenteric lymph node; ODN, oligode-
oxynucleotide; PFA, paraformaldehyde; PP, Peyer’s patch; TLR, Toll-like
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classified on the basis of surface marker expression, such
as the CD11b
 
 
 
CD8
 
 
 
 myeloid-related and the CD11b
 
 
 
CD8
 
 
 
 lymphoid-related subsets (3) as well as the B220
 
 
 
plasmacytoid DC population (4). All of these subsets can be
found in the spleen, where they are either generated locally
from hemopoietic precursors or recruited from the blood
(2, 5). Prototype lymphatic migratory DCs are the Langer-
hans cells (LCs) which efficiently phagocytose and process
antigens in the skin and subsequently locate to the local
draining LNs (6, 7). In addition, a subset of intestinal DCs
was shown to migrate from the lamina propria (LP) and
Peyer’s Patches (PPs) to the mesenteric LN (mLN) through
the afferent lymph (8).
Chemotactic attraction of T lymphocytes by DCs is me-
diated through various constitutive and inducible chemo-
kines. DC-derived CC chemokine 1 (DC-CK1) (CCL18)
and EBV-ligand chemokine (ELC) (CCL19) attract naive
T cells into the T cell zone, while the inflammatory
chemokines monocyte chemoattractant protein (MCP)-1
(CCL2), macrophage inflammatory protein (MIP)-1
 
 
 
 (CCL3),
thymus and activation-regulated chemokine (TARC/
CCL17), and macrophage-derived chemokine (MDC)
(CCL22) mainly recruit activated and memory T cells
(9–13). Although differential effects of the inducible, DC-
derived chemokines on polarization of Th1- versus Th2-
dominated T cell responses have been described, this issue
is still controversial (13–17). CCL17 and CCL22 bind to
the chemokine receptor CCR4, which is highly expressed
on Th2 cells and the CLA
 
 
 
 subset of skin-homing memory
T cells (14, 18, 19). Additionally, it has also been identified
on Langerhans cells, monocytes, NK cells, and platelets. A
functional role of these CCR4 ligands has been implied in
the pathogenesis of allergic airway inflammation, atopic
dermatitis, and septic shock syndrome (20, 21).
To obtain better insight into the regulation of CCL17 ex-
pression and the participation of CCL17-expressing cells in
immune responses, we employed a reporter mouse model
which allows tracking of CCL17-expressing cells in vivo by
insertion of an enhanced green fluorescent protein (EGFP)
cassette into the endogenous murine CCL17 locus. Using
this approach, we demonstrate that CCL17 is expressed in a
population of mature myeloid-related DCs located in most
peripheral lymphoid and nonlymphoid organs. Intriguingly,
however, CCL17 expression cannot be induced in the
spleen, even in the presence of systemic bacterial infection,
indicating that CCL17-mediated attraction of activated/ef-
fector T cells is favored at sites of prevalent environmental
antigenic stimulation, like LNs and the mucosal immune
system. Using CCL17-knockout mice we further show that
absence of this chemokine leads to reduced contact hyper-
sensitivity responses and delayed allograft rejection.
 
Materials and Methods
 
Targeting the Murine ccl17 Locus by Homologous Recombination.
 
A P1 phage library generated from murine genomic DNA of the
strain 129/ola (GenomeSystems) was screened by PCR using the
following 
 
ccl17
 
-specific primers: pCCL17-US 5
 
 
 
-CAT GTG
AAG AAG GCC ATC AGA TTG GTG-3
 
 
 
 and pCCL17-DS 5
 
 
 
-
GAG GGA GGA AGG CTT TAT TCC GTT GC-3
 
 
 
. The re-
sulting P1 clone was mapped by Southern blot hybridization and
fragments containing the coding sequence and parts of the pro-
moter were subcloned into pBluescript (Stratagene). The targeting
vector was constructed in pGEM-4Z in a way that an eGFP
cDNA together with a polyA signal and followed by a neomycin
resistance cassette were inserted in the second exon of the 
 
ccl17
 
gene. Potential endogenous initiation codons in the first exon
were mutated to ATC leaving the start codon of the inserted
EGFP as the only possible start for translation. An additional het-
erologous polyadenylation signal was inserted following the EGFP
gene to ensure transcript stability. A herpes simplex virus thymi-
dine kinase (HSV-TK) cassette was inserted upstream of the tar-
geted sequence (Fig. 1 A). E14.1 ES cells were electroporated
with the linearized targeting vector and G418- and gancyclovir-
resistant ES cell clones were picked. The neomycin resistance cas-
sette was flanked by FRT recombination sites which allowed its
removal from the 
 
ccl17
 
 locus by FLP recombinase expression in
vitro in the targeted ES cell lines. Homologous recombination
was detected by genomic Southern blot hybridization. Correctly
targeted ES cell clones were injected into pseudopregnant foster
mothers. Resulting chimeric mice were backcrossed to C57BL/6
mice, and germline transmission of the targeted allele was con-
firmed by Southern blot analysis with a 5
 
 
 
 flanking probe (see Fig.
1 A) of genomic tail DNA digested with XbaI (Fig. 1 B).
 
Mouse Breeding.
 
Genotyping for the reporter allele was per-
formed by PCR on DNA from tail biopsies with the following
primers: pCCL17–2M 5
 
 
 
-ACT CTC AGG ACA CCT GCT
TCC-3
 
 
 
, pCCL17-bgHpA3 5
 
 
 
-GGG GCA AAC AAC AGA
TGG C-3
 
 
 
 and pCCL17-P4 5
 
 
 
-GAG ACC CTT GAG CCT
GAG AG-3
 
 
 
. CCL17/EGFP reporter mice were on a mixed
C57BL/6/129ola genetic background and were used as het-
erozygous CCL17
 
E/
 
 
 
 or homozygous CCL17
 
E/E
 
 mutants in all
experiments. CCL17
 
 
 
/
 
 
 
 littermates or C57BL/6 mice were used
as controls.
Mice were bred in the SPF animal facility of the Institute for
Medical Microbiology, Immunology and Hygiene of the Techni-
cal University of Munich according to German guidelines for an-
imal care.
 
DC Preparation.
 
Bone marrow (BM)-derived DCs were
generated as described previously (9). Briefly, BM cells were re-
moved from femurs and tibias of reporter mice and control mice,
filtered through a nylon mesh, and 5 
 
 
 
 10
 
5
 
 cells/ml were cul-
tured in RPMI 1640 supplemented with 10% vol/vol heat-inac-
tivated FCS, 
 
l
 
-glutamine, penicillin-streptomycin, HEPES, 2-
ME (all from GIBCO BRL), and 10% supernatant of GM-CSF
transfected X63Ag8–653-cells (22). On day 3, 75% of the cul-
ture supernatants were aspirated and replaced with complete me-
dium. On day 6, the nonadherent cells were harvested and en-
riched for DCs as described below. To enrich DCs from organs
of neonatal or 6–12-wk-old mice, thymus, LN, spleen, lung, co-
lon, or PPs were digested with collagenase (collagenase D;
Roche) and DNase (DNase I; Boehringer) before preparation of
a single-cell suspension. Anti-CD11c (N418) magnetic micro-
beads were used to positively enrich DCs from BM cultures or
total organ cell suspensions (Miltenyi Biotec). In some experi-
ments DC subsets from CCL17
 
E/
 
 
 
 mice were sorted by flow cy-
tometry (MOFLO) on the basis of the expression of CD11c and
EGFP. Purity was 98%.
Skin-derived DCs were prepared by splitting ear skin into dor-
sal and ventral portions and placing them dermal side down on a
1% trypsin-PBS solution, before peeling epidermal sheets fromT
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the underlying dermis and mechanically agitating them over a
stainless steel mesh. Resulting cell suspensions were cultured un-
der the same conditions as BM-derived DCs for 24 h.
 
Histology and In Vitro Phagocytosis Analysis Using Confocal Micros-
copy.
 
Tissue samples were fixed for 30 min up to 2 h in 4%
paraformaldehyde (PFA) at 4
 
 
 
C, washed twice in PBS, and sub-
sequently saturated in 20% sucrose for 8 h before being embed-
ded in tissue-freezing medium (Leica) and snap-frozen in
2-methylbutane (Merck) prechilled with liquid nitrogen. Cry-
ostat sections (7 
 
 
 
m) were fixed in acetone (Merck). Frozen sec-
tions were thawed and mounted with Fluoromount-G (Southern
Biotechnology Associates, Inc.). For measurement of solid parti-
cle phagocytosis in vitro, purified BM-derived DCs were incu-
bated on cover slides for 2 h at 37
 
 
 
C with carboxy-modified mi-
crospheres that fluorescinate in the red (488 nm/605 nm; size:
1 
 
 
 
m diameter; Molecular Probes), the uptake was stopped with
ice-cold 0.1% sodium azide-1% FCS-PBS and fixation with 4%
PFA. Analysis was performed using a laser scanning microscope
(Carl Zeiss MicroImaging, Inc. LSM 510). For paraffin sections
specimens were fixed in 4% buffered formalin for 14 to 24 h and
routinely embedded in paraffin. Tissue sections were obtained
and dried over night at 56
 
 
 
C, dewaxed, rehydrated, and rinsed in
buffer. Pressure cooking in 0.01 M citrate buffer (pH 6.0) was
used for antigen retrieval. Sections were subsequently stained
with antibodies against CD45R (Linaris) and detected using a
biotinylated goat anti rat secondary antibody (Dako) with Strep-
tavidin PE (BD Biosciences).
 
In Vitro and In Vivo Stimulation of BM-, Organ-, or Skin-derived
DCs and B Cells.
 
Mice were injected intraperitoneally or intra-
venously with a sublethal dose of 300 
 
 
 
g LPS (Sigma-Aldrich), or
20 nmol CpG-oligodeoxynucleotide (ODN) 1668 (Tib Molbiol)
and 
 
Listeria monocytogenes
 
 (50,000 listeria/mouse), and organs or
organ-derived DCs were analyzed 15 h (LPS and CpG-ODN) or
4 d (listeria) later. Purified BM or organ-derived DCs were stim-
ulated in vitro for 24 h with 100 ng/ml PAM
 
3
 
Cys (EMC micro-
collections), anti-CD40 (10 
 
 
 
g/ml; BD Biosciences) 10 ng/ml
TNF-
 
 
 
 (R&D Systems), 100 ng/ml 
 
Escherichia coli
 
 LPS Serotype
0127:B8 (Sigma-Aldrich), CPG-ODN 1668 (1 
 
 
 
M), 10 ng/ml
IL-1-
 
 
 
 (R&D Systems), or poly(I:C) (50 
 
 
 
g/ml; Sigma-Al-
drich). B cells were purified from spleen and LNs of CCL17
 
E/
 
 
 
mice using FACS sorting (MOFLO) on the basis of the expres-
sion of B220 followed by incubation with LPS (10 
 
 
 
g/ml), anti-
IgM (10 
 
 
 
g/ml), or anti-CD40 (10 
 
 
 
g/ml; BD Biosciences) for
48 h.
 
Flow Cytometry.
 
Fluorescence staining was performed using
the following antibodies purchased from BD Biosciences: anti-
CD11c (PE labeled or biotinylated), anti–I-A
 
b
 
 (PE labeled or
biotinylated), anti-CD40 (PE labeled), anti-CD86 (PE labeled),
anti-CD11b (PE labeled), and anti-CD8 (PE labeled). Intracellular
cytokine production was measured using anti–IL-12p40/p70 anti-
bodies according to the manufacturers instructions (BD Bio-
sciences). Fluorescence was analyzed using a FACSCalibur™ flow
cytometer and CELLQuest™ software (both Becton Dickinson).
 
Measurement of Proliferative Responses and Cytokines.
 
For Ag-
specific activation of TCR-transgenic T cells titrated numbers of
BM- or LN-derived DCs were pulsed with the peptide for the
dominant epitope of the human C-reactive protein (CRP; 1 
 
 
 
g/
ml) or 5 
 
 
 
 10
 
3
 
 BM- or LN-derived DCs were pulsed with ti-
trated amount of CRP-peptide and cocultered with magnetic-
activated cell sorting (MACS) purified LNs and splenic CD4 cells
from DEP-tg mice (23) for 72 h. Proliferation was measured after
addition of 1 
 
 
 
Ci/well 
 
3
 
[H]-thymidine (Amersham Biosciences)
during the last 17 h of the culture.
Culture supernatants were harvested at the indicated time
points and cytokine concentration was assessed by sandwich
ELISA for CCL17, IFN-
 
 
 
, and IL-10 according to the manufac-
turer’s instructions (R&D Systems). Detection limits were 5 pg/
ml for CCL17, 2 pg/ml for IFN-
 
 
 
, and 4 pg/ml for IL-10.
 
In Vivo Skin Sensitization.
 
Tetramethylrhodamine-5-(and-6)-
isothiocyanate (TRITC) was obtained from Molecular Probes. A
stock solution of 10% TRITC in DMSO was diluted to 1% in a
solvent 50:50 (vol/vol) of acetone and dibutylphtalate just before
application. Mice were painted at the shaved abdomen with 0.4
ml of TRITC solution. Inguinal LNs were isolated as the drain-
ing LNs. Contact hypersensitivity against dinitrofluorobenzene
(DNFB; Sigma-Aldrich) was induced and analyzed as described
(24). Briefly, 17 
 
 
 
l of 0.4% DNFB solution in acetone:olive oil
(4:1) was applied to the shaved abdomen on two consecutive days.
3 d later mice were challenged with 8.5 
 
 
 
l on both sides of one
ear. The contralateral ear was treated with vehicle only. Ear thickness
of both ears was measured using an engineer’s micrometer (Mitu-
toyo) to calculate ear swelling. Alternatively, 0.5% FITC (Sigma-
Aldrich) in acetone:dibutylphthalate (1:1) was used following the
same protocol with the exception that 100 
 
 
 
l solution was applied
for sensitization and 10 
 
 
 
l on both sides of the ear for elicitation.
 
Mouse Heart Transplantation.
 
Vascularized heterotopic heart
transplantation was performed as described previously (25). In
brief, donor hearts were harvested from anaesthesized BALB/c
(H-2
 
d
 
, allogeneic) mice and placed in Brettschneider’s solution
(HTK; Köhler Chemie) until grafting. The donor aorta and pul-
monary artery were anastomosed to the abdominal aorta and vena
cava of the H-2
 
b
 
 (CCL17
 
E/
 
 
 
 or CCL17
 
E/E
 
) recipient mice, respec-
tively. The graft was monitored daily for the presence of palpable
contractions, and was considered rejected, when contractions
ceased as confirmed by laparotomy. Gallium nitrate, GN
[Ga(NO3)] (Sigma-Aldrich) was dissolved in 5% sodium citrate di-
hydrate buffer and administered subcutaneously. Transplant recipi-
ents were treated with 30 mg/kg of GN on the day of transplanta-
tion, day 
 
 
 
1, 
 
 
 
2, 
 
 
 
3 and subsequently every other day until day
30. No additional immunosuppression was given to the mice.
 
Results
 
Generation of CCL17-EGFP Reporter Mice.
 
An EGFP
cDNA was inserted into the murine 
 
ccl17
 
 locus by homolo-
gous recombination in embryonic stem cells (Fig. 1 A). After
FLP-mediated deletion of the neomycin resistance cassette
two independent targeted ES cell lines were used to gener-
ate CCL17-EGFP knockin mice. Mice heterozygous for the
mutated allele (hereafter referred to as CCL17
 
E/
 
 
 
) were
identified by Southern blot analysis of genomic tail DNA
(Fig. 1 B). To verify that EGFP-expressing cells indeed rep-
resent CCL17-producing cells BM-derived DCs from
CCL17
 
E/
 
 
 
 mice were sorted into EGFP
 
 
 
 and EGFP
 
 
 
 sub-
populations and cultured for 15 h. CCL17 protein was de-
tected by ELISA in supernatants of EGFP
 
 
 
CD11c
 
 
 
 DCs
from CCL17
 
E/
 
 
 
 reporter mice in equivalent amounts to
those of total CD11c
 
 
 
 DCs from CCL17
 
 
 
/
 
 
 
 WT mice
(Fig. 1 C). Residual CCL17 production in the sorted
EGFP
 
 
 
CD11c
 
 
 
 DC can be explained by the fact that ap-
proximately half of the cells up-regulated CCL17/EGFP ex-
pression subsequent to cell sorting (unpublished data). LPS
stimulation before cell sorting reduced the proportion of
contaminating EGFP
 
 
 
CD11c
 
 
 
 DCs in the EGFP
 
 
 
CD11c
 
 T
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Figure 1. Generation of CCL17 reporter and CCL17-deficient mice. (A) Targeting strategy for insertion of the EGFP cDNA into the murine CCL17
locus. The murine genomic CCL17 locus with partial restriction map (top), the targeting construct (middle), and the targeted allele before and after neo-
mycin deletion (bottom) are shown. The 3 exons of the CCL17 gene are indicated as gray boxes and the hybridization probe used for Southern blot
analysis as a black bar. The EGFP reporter gene and the neomycin resistance cassette are indicated as open boxes, FRT-sites as black arrows. Restriction
sites: B, BamHI; Xa, XbaI; Xo, XhoI. (B) Representative Southern blot analysis of XbaI digested genomic DNA from targeted ES cell clone and mouse
tail biopsies from WT (CCL17 / ) and heterozygous CCL17 mutant (CCL17E/ ) littermates. The WT and targeted allele give signals at 6 and 4 kb, re-
spectively, after hybridization with the 5  flanking probe. (C) CCL17 production by BM-derived DCs from CCL17E/ , CCL17 / , and homozygous
CCL17-deficient (CCL17E/E) mice. BM-derived DCs from CCL17E/  and CCL17E/E mice were sorted into EGFP CD11c  (black bars) and EGFP 
CD11c  DCs (white bars) and those from CCL17 /  mice as CD11c  cells. All cells were cultured in vitro for 15 h. CCL17 production was measured
by ELISA. * CCL17 protein was not detected in the supernatants of BM-derived DCs from CCL17E/E mice. Shown are data from two independent sorts
from each group. (D) CCL17 production by sorted EGFP CD11c  (black bars) and EGFP-CD11c  DC (white bars) from CCL17E/  mice. BM-derived
DCs from CCL17E/  mice were stimulated with LPS for 15 h in vitro before cell sorting. Sorted EGFP CD11c  (black bars) and sorted EGFP-CD11c 
DCs (white bars) were cultured in vitro for 15 h. CCL17 production was measured by ELISA.T
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DC fraction to 15%. In these cultures CCL17 production
was 14-fold reduced compared with those of EGFP 
CD11c  DCs (Fig. 1 D). Thus, expression of EGFP corre-
lates with CCL17 production in the CCL17E/  mice, ex-
cluding the possibility that the ccl17 locus is allelicly ex-
cluded. Therefore, EGFP  cells from CCL17E/  mice are
hereafter referred to as CCL17  cells. CCL17 protein was
not detectable in the supernatants of cultured BM-derived
DCs from homozygous CCL17-deficient mice (hereafter re-
ferred to as CCL17E/E mice; Fig. 1 C).
CCL17-expressing Cells Reside in Primary and Secondary
Lymphoid Organs but Not in the Spleen. We determined
the localization of CCL17  cells in tissue sections by confo-
cal microscopy. CCL17  cells were clearly identifiable in the
thymus, LN, lung, and the intestine of CCL17E/  mice (Fig.
2). In LNs, CCL17  cells were distributed in the paracortical
T cell zones accumulating in the perifollicular region and
only few cells were located in the follicles (Fig. 3 A). In the
cutaneous LN (cLN), they are additionally found in the sub-
capsular sinus, the site of entry of skin-derived DCs (Fig. 2).
In the lung, CCL17  cells accumulated in the peribronchial
regions beneath the airway epithelium. CCL17  cells were
also found in the PPs, forming a cell layer in the subepithelial
dome, and scattered in the interfollicular region. In the LP of
the colon, CCL17  cells are located in the basal crypts un-
derneath the epithelium. Surprisingly, we could not detect
CCL17  cells in the spleen (Fig. 2), in contrast to all other
lymphoid and nonlymphoid organs investigated.
Using flow cytometry, the frequency of CCL17  cells
was shown to be in the range of 0.25–2% of total cells in
the thymus, LN, and lung of neonatal as well as adult mice
(Fig. 3 B). These cells did not express markers specific for
T cells, NK cells, or macrophages identified as CD11b 
CD11c  cells (unpublished data). Furthermore, CCL17
was rarely expressed in B220  B cells, even after stimula-
tion with LPS, anti-CD40, or anti-IgM for 48 h (Fig. 3, A
and C, left). In contrast, CCL17  cells accounted for 18%
of CD11c  DCs in the thymus, 27 or 17% in the mLN or
cLN, respectively, and  2% of CD11c  cells in the lung
(Fig. 3 C, right). In line with the immunohistological data
and our previous findings that CCL17 mRNA is not ex-
pressed in splenic DCs (9), CCL17  cells could not be de-
tected among CD11c  MACS-enriched splenic DCs
( 0.6%; Fig. 3, B and C). CCL17  DCs were also absent
from the spleen of neonatal reporter mice, whereas the fre-
quency of CCL17  DCs in the neonatal thymus appeared
Figure 2. Localization of green fluorescent cells in CCL17E/  mice. Organs were isolated from CCL17E/  mice, fixed with 4% PFA followed by incu-
bation in 20% sucrose and cryostat sections were analyzed by confocal microscopy. Paraffin sections were used for analysis of the colon.T
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higher as compared with adult mice (Fig. 3 C). These find-
ings demonstrate, that CCL17 is specifically produced by a
subset of DCs which is widely distributed in most lym-
phoid and nonlymphoid tissues of the mouse with the
marked exception of the spleen.
CCL17  DCs Display Phenotypic and Functional Features
of Mature DCs. CCL17  DCs express high levels of the
CD11c leukocyte integrin in the thymus and mLNs,
whereas those in cLNs predominantly possessed intermedi-
ate levels of CD11c (Fig. 3 D). Surface MHC class II and
costimulatory molecules such as CD40 and CD86 were
significantly enhanced in CCL17  DCs as compared with
CCL17  DCs in thymus and LNs (Fig. 4 A). Additionally,
CCL17  DCs in the LNs expressed the DEC-205 multi-
lectin receptor (26, 27), displayed intermediate/high levels
of CD11b, and were CD8  (Fig. 4 A). This was also true
for CCL17  DCs in the thymus and PPs (Fig. 4 A, and un-
published data). Notably, CCL17  DCs did not express the
markers B220 and Gr-1, which in mice identify plasmacy-
toid DC (reference 4; unpublished data). Next, we investi-
Figure 3. CCL17 is expressed
by a subpopulation of DCs. (A)
Paraffin sections of cLNs from
CCL17E/  mice were stained
with anti-CD45R Abs and a
biotinylated goat anti rat sec-
ondary antibody followed by
Streptavidin PE (red) for detec-
tion of B220  cells. (B) Fre-
quency of CCL17  cells among
total cells and among MACS-
enriched CD11c  cells (C,
right) from collagenase-digested
organs of adult (black bars) or
neonatal (gray bars) reporter
mice. B cells were sorted as
B220  cells from spleen or LNs
of adult CCL17E/  mice and
stimulated with the indicated
substances for 48 h (C, left).  
LNs were not investigated in
neonatal reporter mice. (D)
MACS enriched DCs isolated
from collagenase digested thy-
mus, mesenteric LN (mLN), cuta-
neous LN (cLN), and spleen from
control C57BL/6 and CCL17E/ 
mice were stained for CD11c and
analyzed by flow cytometry. The
percentages of cells are indicated
within each quadrant.T
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gated the capacity of CCL17  DCs to prime antigen-spe-
cific T cells in vitro. Purified murine CD4 T cells
expressing a transgenic TCR specific for the human CRP
in the context of I-Ab (23) were cultured with sorted
CCL17  or CCL17  DCs in the presence of hCRP-pep-
tide (89–101). CCL17  BM-derived DCs induced vigor-
ous T cell proliferation in contrast to CCL17  DCs (Fig. 4
B). LN-derived CCL17  DCs also displayed an enhanced
stimulatory ability, even though the difference was less pro-
nounced in this case (Fig. 4 B, middle and bottom). In ad-
dition, BM-derived CCL17  DCs were highly efficient in
stimulating allogeneic T cells in a mixed lymphocyte
response (unpublished data). While CCL17  DCs in-
duced high IFN-  production by transgenic CD4 T cells,
CCL17  BM- or LN-derived DCs were unable to stimu-
late IFN-  production (Fig. 4 C). In contrast, splenic DCs
which we show here to be consistently CCL17-negative
were able to induce T cell responses to similar levels as
CCL17  LN DCs in vitro (unpublished data). We also de-
tected IL-10 at a level of 60 pg/ml in cultures stimulated
with CCL17  BM-derived DCs but less than 4 pg/ml in
those of CCL17  DCs. Hence, in agreement with the en-
hanced stimulatory capacity of CCL17  DCs, this DC sub-
set can induce IFN-  as well as IL-10 production in anti-
gen-specific T cells in vitro.
The phagocytotic capacity of the CCL17  DC subset
was examined by culturing purified BM-derived DCs in
the presence of fluorescent particles. Visualization of
phagocytosis by confocal microscopy revealed that both
CCL17  and CCL17  DC subsets engulfed the particles
(Fig. 4 D). However, the number of fluorescent particles
per cell was much lower in the CCL17  DC population,
Figure 4. CCL17  DCs exhibit a myeloid-related phenotype and possess enhanced stimulatory but diminished phagocytotic capacity. (A) Cytofluori-
metric analysis of DCs isolated by MACS from collagenase digested cLNs and thymus of CCL17E/  mice. The histograms show expression of surface
MHC class II (I-Ab), CD86, and CD40 (top histograms) and lineage-related markers DEC205, CD8, and CD11b (bottom histograms) on gated CCL17 
DCs (shaded histograms) and CCL17  DCs (solid lines). The figure shows one of four representative experiments with similar results. (B) DCs were gen-
erated from the BM (top) or isolated from LNs (middle and bottom) of CCL17E/  mice and sorted into CCL17  DCs (filled diamonds) and CCL17 
DCs (open diamonds). DC subpopulations were pulsed with 1  g/ml CRP peptide (89–101) and cultured with 2   104 MACS purified CD4  T cells
from Dep TCR transgenic mice (top and middle). 5   103 DCs were pulsed with titrated amounts of CRP peptide (89–101) and incubated with purified
CD4  T cells from Dep TCR transgenic mice (bottom). T cell proliferation was determined by (3H)-thymidine incorporation during the final 17 h of a
72 h culture. Data represent the means   SD of triplicate determinations from one of two similar experiments. (C) IFN-  production by CD4  Dep
transgenic T cells after stimulation with CCL17  DCs (black bars) or CCL17  DCs (white bars). Supernatants were collected from the cultures described
in (B) 72 h after stimulation with BM DCs or LN DCs, respectively, and IFN-  secretion was assessed by ELISA. Data are the means plus SD of dupli-
cate determinations. Shown is one of two similar experiments. (D) Diminished phagocytosis of BM-derived CCL17  DCs compared with CCL17 
DCs. Purified BM-derived DCs from CCL17E/  mice were incubated for 2 h with fluorescent microspheres before fixation with 4% PFA on coverslides.
A representative field of cells analyzed by confocal microscopy is shown.T
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indicating that they were less efficient in bead uptake. Only
21   2% of CCL17  DCs phagocytosed more than 4 beads
compared with 60   9% of CCL17  DCs as verified by
FACS® analysis (unpublished data). In summary, CCL17-
producing DCs represent a mature subset of DCs with di-
minished ability of phagocytosis but high capacity of in-
ducing T cell–mediated immune responses.
Epidermal LCs Express CCL17 after Maturation and upon
Entry in Cutaneous LN. EGFP fluorescence could not be
detected in skin sections of naive CCL17E/  reporter mice,
indicating that CCL17 was not constitutively produced by
epidermal LC (Fig. 5 A). Next, we prepared epidermal cell
suspensions from ear sheets and analyzed CCL17 expression
after cytokine exposure in vitro. Whereas no CCL17 ex-
pression was found in freshly isolated LCs, 11 or 13% of LCs
produced CCL17 after treatment with IL-1  or TNF- , re-
spectively (Fig. 5 B). The phenotype of CCL17  DCs in
cLNs resembled the phenotype described for skin-derived
DCs, i.e., high expression of MHC class II and CD40, and
intermediate to high levels of CD11c (Fig. 3 D; reference
28). To investigate whether CCL17  DCs in cLNs were de-
scendants from LCs, we painted the skin with TRITC. 24 h
after application of TRITC we assessed the presence of red
fluorescent cells in the draining LNs (Fig. 5 C). All TRITC-
positive cells that emigrated from the skin to the draining
LNs coexpressed CCL17, demonstrating that LCs up-regu-
late CCL17 in the LNs after antigen uptake and maturation,
in agreement with results presented by Merad et al. (29).
Impaired Contact Hypersensitivity Response in the Absence
of CCL17. To evaluate the functional importance of
CCL17 production by activated Langerhans cells, homozy-
gous CCL17E/E mice carrying a genetic CCL17 deficiency
and heterozygous CCL17E/  mice were sensitized by ab-
dominal painting with DNFB or FITC on two consecutive
days. 3 d later mice were challenged with the respective
haptens. The contact hypersensitivity (CHS) response to
DNFB and FITC measured at 24 h after challenge was sig-
nificantly diminished in CCL17E/E mice compared with
CCL17E/  control mice as demonstrated by a reduced ear
thickness (P   0.01; Fig. 5 D). Thus, CCL17 plays a cru-
cial role in the development of CHS responses.
Prolonged Survival of Cardiac Allografts in the Absence of
CCL17. We studied the impact of CCL17 in allograft re-
jection in a model of heterotopic heart transplantation. To
establish a model of chronic transplant rejection recipient
mice were treated with gallium nitrate known to promote
long-term allograft survival due to immunosuppression
(30). We observed a significantly enhanced acceptance
of allogeneic H-2d heart grafts when transplanted into
CCL17-deficient H-2b recipient mice and also a prolonged
allograft survival time of more than 35 d as compared with
CCL17E/  H-2b recipients (P   0.0001; Mann-Whitney
test; Fig. 6). 85% of CCL17E/E mice still accepted the al-
lograft after 60 d, while it was already rejected in 40% of
CCL17E/  recipients. Even 100 d after transplantation al-
lografts were still accepted by 66% of CCL17E/E mice, but
only by 30% of CCL17E/  mice. Indefinite survival of car-
diac grafts can be seen in a syngeneic donor/recipient strain
combination serving as a control. The markedly enhanced
survival of cardiac allografts and the deficiency in allograft
rejection in CCL17E/E mice suggests that absence of
CCL17 expression in recipient DCs may be responsible for
delayed graft rejection.
Stimulation with Microbial Compounds or Inflammatory Cyto-
kines Augments CCL17 Expression. To explore the impact
of bacterial products or inflammatory mediators on CCL17
expression, BM-derived DCs were stimulated with various
known Toll-like receptor (TLR) ligands and TNF- . The
gram-negative bacterial compound LPS as well as the syn-
thetic lipopeptide PAM3Cys induced a twofold increase in
the percentage of CCL17-expressing DCs after 15 h of cul-
ture and also up-regulated the level of CCL17 expression
(Fig. 7 A). Stimulation with the immunostimulatory CpG
oligodeoxynucleotide 1668 (CpG-ODN) or Poly-(I:C) in-
duced the strongest CCL17 expression (Fig. 7 A). In con-
trast, the level of CCL17 production after treatment with
TNF-  was relatively low. More than 50% of the CCL17 
DCs participated in IL-12 production upon treatment with
CpG-ODN, LPS, or PAM3Cys as determined by intracel-
lular staining with an anti–IL-12p40/p70-specific antibody
(Fig. 7 B). Thus, CCL17 synthesis is strongly induced in
response to various TLR ligands and correlates with in-
creased production of IL-12.
CCL17 Expression in the Spleen Cannot Be Induced by Mi-
crobial Challenge. CCL17 expression upon microbial stim-
ulation in vivo was quantified in various organs 15 h after
intraperitoneal LPS injection. CCL17  DCs were threefold
more frequent among DCs of mLNs compared with those
Figure 5. Expression of CCL17 in epidermal LCs upon maturation and impairment of contact hypersensitivity responses in the absence of CCL17. (A)
Absence of CCL17-expression in the skin of CCL17E/  mice. Cryostat sections of tail skin of reporter mice fixed with 4% PFA were analyzed by confo-
cal analysis. (B) Cell suspensions were prepared by trypsinization of epidermal ear sheets of reporter mice and the phenotype of LCs was determined by
flow cytometry. LCs were gated based on expression of MHC class II I-Ab and analyzed for CCL17/EGFP expression before or 15 h after culture in cy-
tokine-supplemented medium (GMCSF   IL-1  [10 ng/ml] or GMCSF   TNF-  [10 ng/ml]). (C) Up-regulation of CCL17 by epidermal LCs after
contact sensitization and migration to the draining LN. Mice were painted with TRITC dissolved in butylphtalate and acetone (1:1) 24 h before cryostat
sections of draining LNs were analyzed by confocal microscopy. Skin-derived LCs in the LN can be identified by TRITC uptake and appear as red-flu-
orescent cells (first from left). CCL17-expression (green) and merged confocal analysis of green and red fluorescence are shown (second and third from
left). TRITC  cells coexpressing CCL17 can be identified by yellow fluorescence. (D) CCL17-deficient mice display reduced contact hypersensitivity
responses to DNFB and FITC. CHS was induced in CCL17-deficient (CCL17E/E) and CCL17E/  control mice by sensitization with 0.4% DNFB or
0.5% FITC on day 0 and day 1. On day 4, sensitized mice were ear challenged with 0.4% DNFB or 0.5% FITC. Ear thickness was measured before and
24 h after challenge. Data represent mean swelling values   SD obtained with 11 (DNFB) and 10 (FITC) mice in two independent experiments. The
differences between mean values derived from CCL17E/E and CCL17E/  are statistically significant (P   0.01).T
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of saline injected mice (Fig. 8 A). Notably, the increase in
frequency of CCL17  DCs in PPs and lung was even more
profound (6–7-fold) and associated with higher levels of
CCL17 expression as compared with the other organs in-
vestigated (Fig. 8 B). Similar results were obtained upon in-
jection of reporter mice with CpG-ODN (unpublished
data), known to induce an array of inflammatory cytokines
in vivo (31). Although up-regulation of MHC class II mol-
ecules and costimulatory molecules such as CD40 and
CD86 on splenic DCs upon intraperitoneal stimulation
confirmed activation of DCs in vivo, the expression of
CCL17 in the spleen did not exceed background levels in
contrast to the mLN (see Fig. 8 C, and unpublished data).
Intravenous application of these stimuli led to the same re-
sults (unpublished data). To investigate whether CCL17
expression in the spleen was induced during acute bacterial
infection we infected mice with Listeria monocytogenes
which has been shown to lead to splenic DC maturation
(32). The absence of CCL17 expression in the inflamed
spleens 4 d after bacterial challenge is striking (Fig. 8 C),
considering that at this time point listeria colonize the
spleen and induce a severe inflammatory response (33), ac-
companied by splenomegaly (unpublished data).
To exclude that diminished accessibility of splenic DCs
for circulating bacterial compounds or activation-induced
DC emigration might be the cause for the absence of
CCL17 in this environment, we cultured splenic DCs for
24 h in the presence of inflammatory mediators, proven to
up-regulate CCL17 expression in BM-derived DCs (see
Fig. 7). Remarkably, the level of EGFP/CCL17 expression
Figure 6. Enhanced survival of cardiac allografts in the absence of
CCL17. Heterotopic mouse heart transplantation using BALB/c donor
hearts and either CCL17E/E, CCL17E/ , or BALB/c mice as recipients
was performed as described in Materials and Methods. Recipient mice
were injected intraperitoneally with 30 mg/kg of Gallium nitrate on the
day of transplantation, day  1,  2,  3, and subsequently every other
day until day 30. Cardiac allografts were monitored daily for survival. Re-
sults are expressed as percentage of mice with a viable allograft.
Figure 7. CCL17 expression is induced by various TLR ligands and correlates with IL-12 production. (A) Purified BM-derived DCs from CCL17E/ 
mice were cultured for 15 h in the presence of the TLR ligands PAM3Cys, Poly-(I:C), LPS, and CpG-ODN or the proinflammatory cytokine TNF- 
and EGFP expression was analyzed by flow cytometry. (B) Flow cytometric analysis of intracellular IL-12 production and EGFP expression in the same
cultures as described in panel A. Representative data from one of three experiments are shown.T
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was not increased by splenic DCs exposed to LPS,
PAM3Cys, CpG-ODN, or  CD40 (Fig. 8 D) and CCL17
protein was undetectable in CpG-ODN stimulated splenic
DC supernatants by ELISA (unpublished data), demon-
strating that DCs located in the spleen fail to produce
CCL17 after maturation.
Discussion
Using an in vivo EGFP reporter system, we have eluci-
dated the expression and function of the chemokine
CCL17 and its regulation after stimulation with microbial
components. Analysis of CCL17E/  mice demonstrated
that CCL17  DCs belong to the most mature CD8 
CD11b DEC205  DC population which is part of the so
called myeloid-related DC population and includes the de-
scendants of LCs of the skin (34). CCL17 expression may
be induced by environmental antigenic stimulation, as
CCL17  DCs are preferentially located in skin or gut
draining LNs and at mucosal surfaces, albeit the presence of
a high proportion of CCL17  DCs in the neonatal thymus
as well as GM-CSF–stimulated BM cultures suggests that
CCL17 may also be expressed constitutively.
In PPs, CD11b  DCs are anatomically restricted to the
subepithelial dome representing the main entry site of in-
testinal antigens and microbes. From there they migrate to
the interfollicular region and accomplish T cell contact af-
ter microbial challenge (35, 36). Interestingly, CCL17 
Figure 8. Accumulation of CCL17  DCs upon LPS stimulation in various lymphoid organs, but absence of CCL17-expressing cells in the spleen dur-
ing inflammatory responses. (A) Flow cytometric analysis of mLNs of unstimulated C57BL/6, control, and LPS-stimulated CCL17E/  mice. DCs were
prepared from collagenase digested mLNs from untreated mice or 15 h after LPS stimulation and enriched by MACS. Expression of CD11c, MHC class
II (I-Ab), and CD86 were determined. The percentages of cells are indicated in each quadrant. Representative data from one of four independent exper-
iments are shown. (B) MACS enriched DCs of PPs (top) and lung (bottom) of C57BL/6 control mice, unstimulated CCL17E/  mice, and CCL17E/ 
mice 15 h after LPS stimulation were gated as CD11c  cells and analyzed for CCL17 expression. Values shown in the histograms represent the percent-
age of CCL17-positive cells. One representative of three experiments is shown. (C) Confocal analysis of cryostat sections of mLN (top) and spleen
(bottom) from CCL17E/  mice 15 h after injection of LPS or CpG-ODN, or 4 d after infection with Listeria monocytogenes, as indicated. (D) CCL17 ex-
pression is not induced in splenic DC of CCL17E/  mice after in vitro stimulation. Flow cytometric analysis was performed on MACS purified splenic
DCs after incubation with GMCSF and LPS, PAM3Cys, CpG-ODN, or  CD40 for 24 h. Cells were analyzed for CD11c and EGFP expression.T
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DCs locate to the same areas in PPs, indicating that
CCL17 is highly expressed in those intestinal DCs which
are actively involved in the uptake of luminal antigens. In
addition, an alternative route of bacterial uptake in the in-
testine was proposed in which DCs localized in the LP
penetrate the gut epithelium by opening tight junctions
(37). Subepithelial localization of CCL17  cells in the basal
crypts of the colonic LP (Fig. 2) points to a potential role
of CCL17 in this kind of antigen uptake. The identifica-
tion of CCL17  DCs at important antigen entry sites into
the intestinal immune system is in line with the fact that
intestinal CCL17 expression is up-regulated in the context
of inflammatory bowel disease (38). Up-regulation of
CCL17 through receptors of the innate immune system
was particularly evident upon application of ligands for
TLR 1/2, 3, 4, or 9, like Pam3Cys, Poly-(I:C), LPS, or
CpG-ODN (reference 39; Fig. 7). As it is known that sys-
temic application of LPS induces migration of DCs from
nonlymphoid tissues into lymphoid organs (40), it is likely
that enhanced recruitment of peripheral DCs accounts at
least in part for the absolute increase in CCL17-expressing
DCs in LNs and PPs.
An outstanding result of the present analysis is that
splenic DCs, in sharp contrast to DCs isolated from other
lymphoid organs, fail to express CCL17 in response to mi-
crobial stimuli. This finding is further strengthened by the
fact that CCL22, the second known CCR4 ligand, is also
undetectable in the spleen following intravenous LPS in-
jection (41). It is unlikely that circulating LPS is not acces-
sible to splenic DCs, as these cells expressed other activa-
tion markers upon systemic LPS stimulation and also did
not respond with CCL17 synthesis after in vitro stimulation
(Fig. 8). A more likely explanation for the lack of CCL17
expression in the spleen is that splenic DCs are in a distinct
differentiation stage which prohibits CCL17/CCL22 pro-
duction. It is conceivable that CCL17  DCs represent mi-
gratory cells which preferentially home to LNs but not to
the spleen as was shown for epidermal LCs (42). Alterna-
tively, CCL17 expression may be actively suppressed by
the splenic microenvironment or specifically induced by
cell types which are absent from the spleen, e.g., epithelial
cells (43).
It is an intriguing question why the production of
CCR4 ligands which preferentially attract activated/mem-
ory T cells (9, 11, 13, 15) should be undesirable in the
spleen, considering the well known capacity of splenic DCs
for antigen presentation and T cell priming (1). Splenecto-
mized patients have an increased susceptibility to infections
with encapsulated bacteria (44) which is mostly due to a
deficiency of protective bacterial polysaccharide specific
antibodies of the thymus-independent (TI)-2 type (45).
Rapid production of TI-2 antibodies is of major impor-
tance when the host has to eliminate pathogens quickly in
the case of hematogenic spread of bacterial or viral infec-
tions (46), and is best induced in the marginal zone of the
spleen as a filter of blood-borne antigens (47–50). Conse-
quently, it may even be detrimental to simultaneously trig-
ger TI immune responses and to attract effector/memory T
cells into the spleen because of a possible incompatibility of
the corresponding cytokine responses (51). Therefore, the
differential function of splenic versus LN DCs regarding
CCL17/CCL22 production may ascertain the develop-
ment of the appropriate type of immune response to sys-
temic versus local infections.
The ability of CCL17  DCs to produce IL-12 and to in-
duce proliferation as well as IFN-  production of antigen-
specific T cells (Figs. 4 and 7) argues for an immunostimu-
latory function of these cells. In comparison to CCL17 
BM- or LN-derived DCs the CCL17  DC subset repre-
sents the more potent APC population. In line with these
results, there is a marked reduction in the T cell–dependent
CHS response toward reactive haptens in CCL17E/E mice
as compared with CCL17E/  control mice, suggesting that
LC inefficiently attract hapten-specific effector T cells in
the absence of CCL17. However, it may also be possible
that CCL17 is also involved in regulating the migration of
LCs themselves, as it was reported in human that LCs ex-
press CCR4 in inflamed skin (52). Cross-priming of viral
antigens after intradermal immunization has recently been
demonstrated to be mediated by CD8  skin-derived DCs
(53) which phenotypically resemble CCL17  DCs in
cLNs. In addition, subcutaneous immunization with a tu-
mor cell vaccine which requires cross-priming by host
APCs was shown to be of much higher efficiency than in-
trasplenic immunization (54). The important role of LNs in
the development of cutaneous hypersensitivity responses
(42) as well as efficient antiviral immune responses (55) was
further underlined by immunization of mouse mutants
which are congenitally deficient in the development of pe-
ripheral LNs or the spleen.
Our studies provide the first evidence that CCL17 pro-
duction by recipient cells plays a crucial role in the devel-
opment of allograft rejection, as the survival of fully MHC-
disparate cardiac grafts is markedly enhanced in CCL17E/E
recipient mice in a chronic transplantation model. Prior
studies also indicated that the interaction of chemokines
with their respective receptors is important in graft rejec-
tion (56, 57). However, allograft survival time in mice
deficient for receptors for DC-derived chemokines was sig-
nificantly increased only in the presence of immunosup-
pression induced by Cyclosporin A (CsA; reference 58).
Given recent evidence for a participation of CD4 T cells
and NK cells in the induction of chronic transplant rejec-
tion (25, 59), diminished attraction of CCR4-bearing ef-
fector cells to the graft or local draining LNs may be a po-
tential mechanism for enhanced transplant acceptance in
the absence of CCL17.
Additional data on the functional role of CCL17 have
been obtained by treatment of mice with CCL17-specific
antibodies, by which the development of antigen-specific
asthmatic lung reactions (60) as well as Propionibacterium ac-
nes induced liver pathology (61) could be inhibited. Unex-
pectedly, however, CCR4-deficient mice were not pro-
tected from allergic airway inflammation but rather showed
a marked resistance to LPS-induced septic shock syn-
dromes (21) thus challenging the common view thatT
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CCL17 and CCL22 preferentially promote T cell responses
with a Th2 bias (13, 15, 17). We and others have previ-
ously shown that both Th2 and Th1 cells can be attracted
to CCL17 or CCL22 (9, 11), and CCR4 expression was
detected on ex vivo isolated human CD4  memory T cells
carrying Th1 as well as Th2 markers (16). Taken together,
a functional role of CCL17 as a chemoattractant of effec-
tor/memory T cells is evident but this may not be re-
stricted to Th2 cells only. Expression of CCR4 has also
been detected on the CD25  regulatory T cell subset (62)
suggesting that CCL17 may possibly also participate in
feedback inhibition of ongoing immune responses.
In conclusion, we have demonstrated that the splenic
DC population of mice differs from the majority of
CD11b  DCs derived from other lymphoid organs and
skin or mucosal surfaces regarding the production of the T
cell attractant chemokine CCL17. This result indicates that
chemokine usage by DCs is distinctly regulated in second-
ary lymphoid organs depending on positioning of the organ
in central versus peripheral immune surveillance.
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